Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2012

01.04.2012 | Preclinical Study

Bone metastasis in a novel breast cancer mouse model containing human breast and human bone

verfasst von: Tian-Song Xia, Guo-Zhu Wang, Qiang Ding, Xiao-An Liu, Wen-Bin Zhou, Yi-Fen Zhang, Xiao-Ming Zha, Qing Du, Xiao-Jian Ni, Jue Wang, Su-Yu Miao, Shui Wang

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

In practice, investigations for bone metastasis of breast cancer rely heavily on models in vivo. Lacking of such ideal model makes it difficult to study the whole process or accurate mechanism of each step of this metastatic disease. Development of xenograft mouse models has made great contributions in this area. Currently, the best animal model of breast cancer metastasizing to bone is NOD/SCID-hu models containing human bone, which makes it possible to let the breast cancer cells and the bone target of osteotropic metastasis be both of human origin. We have developed a novel mouse model containing both human bone and breast, and proved it functional and reliable. In this study, a set of human breast cancer cell line including MDA-MB-231, MDA-MB-231BO, MCF-7, ZR-75-1 and SUM1315 were characterized their osteotropism in this model. A specific cell line SUM1315 made species-specific bone metastasis, certifying the osteotropism-identification utility of the novel mouse model. Furthermore, gene expression and microRNA expression profiling analysis were done to the two SUM1315 derived sub lines isolated and purified from the orthotopic and metastatic xenograft. In addition, to demonstrate the disparity between the “spontaneous” and “forced” bone metastasis in mouse model, MDA-MB-231 cells were inoculated into both the human implants in this model simultaneously, and then primary cultured and profiling analyzed. Supported by overall results of profiling analyses, this study suggested the novel model was a useful tool for understanding, preventing and treating bone metastasis of breast cancer, meanwhile it had provided significant information for further investigations.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
4.
Zurück zum Zitat Coleman RE (2002) Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol 25(6 Suppl 1):S32–S38PubMedCrossRef Coleman RE (2002) Future directions in the treatment and prevention of bone metastases. Am J Clin Oncol 25(6 Suppl 1):S32–S38PubMedCrossRef
12.
Zurück zum Zitat Bauerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR (2005) Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115(2):177–186. doi:10.1002/ijc.20840 PubMedCrossRef Bauerle T, Adwan H, Kiessling F, Hilbig H, Armbruster FP, Berger MR (2005) Characterization of a rat model with site-specific bone metastasis induced by MDA-MB-231 breast cancer cells and its application to the effects of an antibody against bone sialoprotein. Int J Cancer 115(2):177–186. doi:10.​1002/​ijc.​20840 PubMedCrossRef
13.
Zurück zum Zitat Waltregny D, Bellahcene A, de Leval X, Florkin B, Weidle U, Castronovo V (2000) Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15(5):834–843. doi:10.1359/jbmr.2000.15.5.834 PubMedCrossRef Waltregny D, Bellahcene A, de Leval X, Florkin B, Weidle U, Castronovo V (2000) Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15(5):834–843. doi:10.​1359/​jbmr.​2000.​15.​5.​834 PubMedCrossRef
14.
Zurück zum Zitat Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, Ganss B, Cheifetz S (2000) Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 18(3):253–260PubMedCrossRef Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, Ganss B, Cheifetz S (2000) Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis 18(3):253–260PubMedCrossRef
15.
Zurück zum Zitat Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121–127. doi:10.1038/nm0202-121 PubMedCrossRef Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardo-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R (2002) Steps toward mapping the human vasculature by phage display. Nat Med 8(2):121–127. doi:10.​1038/​nm0202-121 PubMedCrossRef
19.
Zurück zum Zitat Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T (1996) E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 56(17):4063–4070PubMed Mbalaviele G, Dunstan CR, Sasaki A, Williams PJ, Mundy GR, Yoneda T (1996) E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 56(17):4063–4070PubMed
20.
Zurück zum Zitat Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537–549PubMedCrossRef Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordon-Cardo C, Guise TA, Massague J (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3(6):537–549PubMedCrossRef
21.
Zurück zum Zitat Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML (1999) Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59(8):1987–1993PubMed Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ, Cher ML (1999) Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59(8):1987–1993PubMed
22.
Zurück zum Zitat Shtivelman E, Namikawa R (1995) Species-specific metastasis of human tumor cells in the severe combined immunodeficiency mouse engrafted with human tissue. Proc Natl Acad Sci USA 92(10):4661–4665PubMedCrossRef Shtivelman E, Namikawa R (1995) Species-specific metastasis of human tumor cells in the severe combined immunodeficiency mouse engrafted with human tissue. Proc Natl Acad Sci USA 92(10):4661–4665PubMedCrossRef
23.
Zurück zum Zitat Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A (2001) Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 61(5):2177–2182PubMed Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A (2001) Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 61(5):2177–2182PubMed
24.
25.
Zurück zum Zitat Yang W, Lam P, Kitching R, Kahn HJ, Yee A, Aubin JE, Seth A (2007) Breast cancer metastasis in a human bone NOD/SCID mouse model. Cancer Biol Ther 6(8):1289–1294. doi:4504 PubMed Yang W, Lam P, Kitching R, Kahn HJ, Yee A, Aubin JE, Seth A (2007) Breast cancer metastasis in a human bone NOD/SCID mouse model. Cancer Biol Ther 6(8):1289–1294. doi:4504 PubMed
26.
27.
Zurück zum Zitat Xia TS, Wang J, Yin H, Ding Q, Zhang YF, Yang HW, Liu XA, Dong M, Du Q, Ling LJ, Zha XM, Fu W, Wang S (2010) Human tissue-specific microenvironment: an essential requirement for mouse models of breast cancer. Oncol Rep 24(1):203–211PubMed Xia TS, Wang J, Yin H, Ding Q, Zhang YF, Yang HW, Liu XA, Dong M, Du Q, Ling LJ, Zha XM, Fu W, Wang S (2010) Human tissue-specific microenvironment: an essential requirement for mouse models of breast cancer. Oncol Rep 24(1):203–211PubMed
28.
Zurück zum Zitat Garcia T, Jackson A, Bachelier R, Clement-Lacroix P, Baron R, Clezardin P, Pujuguet P (2008) A convenient clinically relevant model of human breast cancer bone metastasis. Clin Exp Metastasis 25(1):33–42. doi:10.1007/s10585-007-9099-1 PubMedCrossRef Garcia T, Jackson A, Bachelier R, Clement-Lacroix P, Baron R, Clezardin P, Pujuguet P (2008) A convenient clinically relevant model of human breast cancer bone metastasis. Clin Exp Metastasis 25(1):33–42. doi:10.​1007/​s10585-007-9099-1 PubMedCrossRef
29.
Zurück zum Zitat Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2008) Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 68(19):7795–7802. doi:10.1158/0008-5472.CAN-08-1078 PubMedCrossRef Pratap J, Wixted JJ, Gaur T, Zaidi SK, Dobson J, Gokul KD, Hussain S, van Wijnen AJ, Stein JL, Stein GS, Lian JB (2008) Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res 68(19):7795–7802. doi:10.​1158/​0008-5472.​CAN-08-1078 PubMedCrossRef
30.
Zurück zum Zitat Neudert M, Fischer C, Krempien B, Seibel MJ, Bauss F (2008) A rapid histological score for the semiquantitative assessment of bone metastases in experimental models of breast cancer. Onkologie 31(10):521–527. doi:10.1159/000151622 PubMedCrossRef Neudert M, Fischer C, Krempien B, Seibel MJ, Bauss F (2008) A rapid histological score for the semiquantitative assessment of bone metastases in experimental models of breast cancer. Onkologie 31(10):521–527. doi:10.​1159/​000151622 PubMedCrossRef
33.
Zurück zum Zitat Cailleau R, Young R, Olive M, Reeves WJ Jr (1974) Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53(3):661–674PubMed Cailleau R, Young R, Olive M, Reeves WJ Jr (1974) Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 53(3):661–674PubMed
Metadaten
Titel
Bone metastasis in a novel breast cancer mouse model containing human breast and human bone
verfasst von
Tian-Song Xia
Guo-Zhu Wang
Qiang Ding
Xiao-An Liu
Wen-Bin Zhou
Yi-Fen Zhang
Xiao-Ming Zha
Qing Du
Xiao-Jian Ni
Jue Wang
Su-Yu Miao
Shui Wang
Publikationsdatum
01.04.2012
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2012
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1496-0

Weitere Artikel der Ausgabe 2/2012

Breast Cancer Research and Treatment 2/2012 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.